American biotechnology company Moderna Inc which is currently conducting trials for its messenger RNA based COVID-19 vaccine candidate has revealed that an analysis of the early-stage data of its vaccine-induced similar immune responses in both older adults and younger participants.
The drug developer which seen as one of the leading U.S. contenders in the race to develop a safe and effective vaccine against the novel coronavirus with its candidate, mRNA-1273, is already in the Phase 3 stage of human testing.
The latest report came from its interim data from the Phase 1 study which included new analysis from 20 additional people and details on how the vaccine performs in older people.
The firm said the immune responses in those aged between 56 and 70 years, above 70 and those in the age-group of 18 and 55 were similar. The study looked at 100 microgram dosage that has been selected for the larger Phase 3 trial.
The data is being presented at the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices meeting.
Moderna, which has no drugs in the market, has received nearly $1 billion from the U.S. government under its Operation Warp Speed, an initiative to speed up vaccine development for COVID-19. It has also struck a $1.5 billion supply agreement with the United States.
